The influence of aripiprazole and olanzapine on neurotransmitters level in frontal cortex of prenatally stressed rats

被引:7
作者
Ratajczak, P. [1 ]
Kus, K. [1 ]
Golembiowska, K. [2 ]
Noworyta-Sokolowska, K. [2 ]
Wozniak, A. [3 ]
Zaprutko, T. [1 ]
Nowakowska, E. [1 ]
机构
[1] Poznan Univ Med Sci, Dept Pharmacoecon & Social Pharm, Dabrowskiego 79, PL-60529 Poznan, Poland
[2] Polish Acad Sci, Inst Pharmacol, Smetna 12, PL-31343 Krakow, Poland
[3] Poznan Univ Med Sci, Dept Toxicol, Dojazd 30, PL-60631 Poznan, Poland
关键词
Animal model of schizophrenia; Prenatal stress; Aripirazole; Olanzapine; Microdialysis; Neurotransmitters; MEDIAL PREFRONTAL CORTEX; IN-VIVO; DOPAMINE RELEASE; INCREASES DOPAMINE; ANTIPSYCHOTIC-DRUG; NUCLEUS-ACCUMBENS; SPATIAL MEMORY; NOREPINEPHRINE; SCHIZOPHRENIA; NORADRENALINE;
D O I
10.1016/j.etap.2016.07.007
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
Objectives: The study aims to verify whether alterations in the level of neurotransmitters have occurred in prenatally stressed rats (animal model of schizophrenia), and whether aripiprazole (ARI) and olanzapine (OLA) modify this level. Methods: The effects of ARI (1.5 mg/kg) and OLA (0.5 mg/kg) were studied by means of microdialysis in freely moving rats (observation time 120 min). The level of neurotransmitters (DA, 5-HT, NA) and their metabolites (DOPAC, HVA, 5-HIAA) was analyzed by HPLC with coulochemical detection. Results: Obtained results indicate that after a single administration of ARI and OLA in the prenatally stressed rats the increase of DA, DOPAC, and 5-HT was observed. In turn ARI administration increase the level of HVA and 5-HIAA and also decrease the level of NA. After OLA administration the level of NA and HVA increased and no significant change in 5-HIAA was observed. Conclusion: Alterations observed as a result of ARI and OLA administration may be pivotal in identifying animal models of mental disorders and in the analysis of neuroleptics effectiveness. (C) 2016 Elsevier B.V. All rights reserved.
引用
收藏
页码:122 / 130
页数:9
相关论文
共 45 条
[1]   The antipsychotics clozapine and olanzapine increase plasma glucose and corticosterone levels in rats:: Comparison with aripiprazole, ziprasidone, bifeprunox and F15063 [J].
Assie, Marie-Bernadette ;
Carilla-Durand, Elisabeth ;
Bardin, Laurent ;
Maraval, Mireille ;
Aliaga, Monique ;
Malfetes, Nathalie ;
Barbara, Michele ;
Newman-Tancredi, Adrian .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2008, 592 (1-3) :160-166
[2]   Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology [J].
Barnes, Thomas R. E. .
JOURNAL OF PSYCHOPHARMACOLOGY, 2011, 25 (05) :567-620
[3]   Dopamine release induced by atypical antipsychotics in prefrontal cortex requires 5-HT1A receptors but not 5-HT2A receptors [J].
Bortolozzi, Analia ;
Masana, Merce ;
Diaz-Mataix, Llorenc ;
Cortes, Roser ;
Cecilia Scorza, Maria ;
Gingrich, Jay A. ;
Toth, Miklos ;
Artigas, Francesc .
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2010, 13 (10) :1299-1314
[4]   Influence of aripiprazole on the antidepressant, anxiolytic and cognitive functions of rats [J].
Burda, Kinga ;
Czubak, Anna ;
Kus, Krzysztof ;
Nowakowska, Elzbieta ;
Ratajczak, Piotr ;
Zin, Jennifer .
PHARMACOLOGICAL REPORTS, 2011, 63 (04) :898-907
[5]   Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors [J].
Burris, KD ;
Molski, TF ;
Xu, C ;
Ryan, E ;
Tottori, K ;
Kikuchi, T ;
Yocca, FD ;
Molinoff, PB .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 302 (01) :381-389
[6]   Olanzapine: a basic science update [J].
Bymaster, F ;
Perry, KW ;
Nelson, DL ;
Wong, DT ;
Rasmussen, K ;
Moore, NA ;
Calligaro, DO .
BRITISH JOURNAL OF PSYCHIATRY, 1999, 174 :36-40
[7]   Effects of aripiprazole, olanzapine, and haloperidol in a model of cognitive deficit of schizophrenia in rats: relationship with glutamate release in the medial prefrontal cortex [J].
Carli, Mirjana ;
Calcagno, Eleonora ;
Mainolfi, Pierangela ;
Mainini, Ester ;
Invernizzi, Roberto W. .
PSYCHOPHARMACOLOGY, 2011, 214 (03) :639-652
[8]  
Czubak A, 2010, J PHYSIOL PHARMACOL, V61, P339
[9]   On the origin of cortical dopamine: Is it a co-transmitter in noradrenergic neurons? [J].
Devoto, P ;
Flore, G .
CURRENT NEUROPHARMACOLOGY, 2006, 4 (02) :115-125
[10]  
FULLER RW, 1989, J PHARMACOL EXP THER, V248, P50